Intrathecal administration of 131I radiolabelled monoclonal antibody as a treatment for neoplastic meningitis.
Fifteen patients with neoplastic meningitis received a single intrathecal injection of between 11 and 60 mCi of a 131I radiolabelled monoclonal antibody (MoAb), chosen for its immunoreactivity to tumour. Major toxicity was manifest as nausea, vomiting and headache (7/15 patients), reversible bone marrow suppression (3/8 patients) and seizures (2/15 patients). Nine patients were evaluable for either a tumour or clinical response. Six of these demonstrated an event-free response that was maintained for periods of between 7 and 26 months.
Moseley
R P
RP
Department of Neurosurgery, Frenchay Hospital, Bristol, UK.
Davies
A G
AG
Richardson
R B
RB
Zalutsky
M
M
Carrell
S
S
Fabre
J
J
Slack
N
N
Bullimore
J
J
Pizer
B
B
Papanastassiou
V
V
D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D001853:Bone Marrow / Q000528:radiation effects; D002423:Cause of Death; D006801:Humans; D007278:Injections, Spinal; D007457:Iodine Radioisotopes / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D008577:Meningeal Neoplasms / Q000401:mortality / Q000628:therapy*; D008581:Meningitis / Q000401:mortality / Q000628:therapy*; D010865:Pilot Projects; D015996:Survival Rate
D000911:Antibodies, Monoclonal; D007457:Iodine Radioisotopes